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PCIThemajority of patients with acute coronary syndrome (ACS) are elderly. Limited evidencemakes decision-making
on the use of percutaneous coronary intervention (PCI)mainly empirical. Old age is one risk factor, but other factors
than agemay have an impact onmortality aswell. Therefore, we investigated predictors of long-termall-causemor-
tality among octogenarians who have undergone PCI due to ACS. A total of 182 patients≥ 80 years who underwent
PCI during 2006–2007 at Sahlgrenska University Hospital were studied consecutively from recorded clinical data.
All-cause ﬁve-year mortality of follow-up was 46.2%. Mean age was 83.7 ± 2.8, 62% were male, 76% were in sinus
rhythm, and 42% had left ventricular ejection fraction b 45%. Indications for PCI were STEMI (52%), NSTEMI (36%)
and unstable angina (11%). Multivariate analysis in two steps identiﬁed atrial ﬁbrillation, moderate tricuspid
valve regurgitation, moderate mitral valve regurgitation, dependency in ADL and eGFR ≤ 30 ml/min at the ﬁrst
step and moderate mitral valve regurgitation, atrial ﬁbrillation and eGFR ≤ 30 ml/min at the last step, as
independent predictors of all-cause mortality. Kaplan Meier analysis of positive parameters from both
steps of multivariate analysis showed high signiﬁcant difference in survival between patients having
these parameters and those who were free from these parameters, with worst prognosis in patients with
accumulation of these parameters. Accordingly, we have, in an octogenarian patient cohort who suffered
from ACS, undergone PCI in daily clinical practice, identiﬁed ﬁve prognostic predictors for all-cause death
after ﬁve years' follow-up.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Current guidelines on the use of reperfusion therapy in acute coro-
nary syndrome (ACS) are based on data derived from randomized clin-
ical trials (RCTs) [1–3]. However, data regarding percutaneous coronary
intervention (PCI) in octogenarians are not only very limited but
also inconsistent. There are data in favor of PCI in the elderly [4–6].
However, several observational studies have demonstrated that oldngiotensin receptor blockers;
ortic valve stenosis; AV-block,
CABG, Coronary artery bypass
R, Mitral valve regurgitation;
ction; PA-P, Pulmonary atrial
farction; TR, Tricuspid valve
nska University Hospital/Östra,
wani).
nd Ltd. This is an open access article unage is associated with both higher in-hospital mortality and frequent
complications such as renal failure and bleedings after PCI [7,8]. Results
from studies on mid- and long-term outcomes of PCI are more ambigu-
ous. For example, incidence rates among elderly patients of major
adverse cardiac events (MACE), deﬁned as the combined events of
death, revascularization and myocardial infarction, have been found to
be both higher and similar to rates among younger patients [9–12].
The paucity and inconsistency of data on the use of PCI in the elderly
have several implications. In our daily clinical practice, it is difﬁcult for
physicians to make well-grounded decisions on the use of PCI in the el-
derly. Elderly patients have been found to be less likely than younger
patients to undergo PCI, despite adjusting for contraindications and
co-morbidities that may be of relevance, partly because some of the
existing data suggest that age is associated with negative outcomes
[13–15]. The suggestion that elderly patients are sometimes withheld
PCI solely because of their age is contrary to prevailing ethical principles.
Moreover, the elderly constitute a heterogeneous group. The term
‘elderly’ is a broad term comprising the “young” old (65–74 years),der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
139S.B. Barywani et al. / IJC Heart & Vessels 4 (2014) 138–144the “older” old (75–84 years) and the “oldest” old (≥85 years) [16]
with considerable individual variation in co-morbidities and physical
capabilities. In view of the heterogeneity of the elderly patient group it
is likely that some of them have better prospects of gaining from PCI
in the setting of ACS than others. Therefore it is essential to identify
prognostic factors that indicate increased risk for death in patients
with acute coronary syndrome despite PCI, which might be helpful in
decision making in clinical practice.2. Materials and methods
2.1. Study cohort
A total of 182patients≥ 80 yearswhohad been treatedwith PCI due
to acute coronary syndrome (ACS) during 2006–2007 at Sahlgrenska
University Hospital, Gothenburg,were included consecutively and stud-
ied retrospectively from January 2 toMay 30, 2012. All together 145 pa-
rameters covering social, functional andmedical domains were entered
into a database. The time-period 2006–2007 was chosen to allow a
follow-up period of at least ﬁve years. PCI procedures for the speciﬁed
age group and time period were identiﬁed from the hospital registry.
The selection process is illustrated in Fig. 1. Three exclusion criteria for
the study were applied. Firstly, since the catchment area of the
Sahlgrenska University Hospital for performing PCI during emergency
hours is larger than during ofﬁce hours a substantial amount of the pro-
cedureswere performed in individualswho are not normally patients of
the hospital. These patientswere excluded from the study sincemedical
records from before and after the procedure were not accessible. Sec-
ondly, in some cases two or more PCI procedures were performed in
the same patient. In these cases only the ﬁrst PCI the individual patient
underwent at the age of ≥80 years were studied. Thirdly, since the ob-
jective of the study was to evaluate prognosis after PCI in ACS, elective
PCI procedures with the indication of stable angina pectoris were ex-
cluded (Fig. 1). This is based on the fact that current PCI-indication in
the case of stable angina is to relive symptoms rather than prognostic
beneﬁt. The study protocol was approved by the Ethical Committee at
the University of Gothenburg.Fig. 1. Outline for patient selection process.2.2. Laboratory analyses
All laboratory variables examined were analyzed routinely by the
laboratory services provided by the Clinical Chemistry Laboratory
at Sahlgrenska University Hospital. The estimated glomerular
ﬁltration rate (eGFR) was calculated using the Cockcroft–Gault formula
in ml/min.
2.3. Statistics
The results are presented as percentage andmean± standard devi-
ation (SD) or as median and inter-quartile range (IQR) when values
were not normally distributed. In the case of continuous variables, sta-
tistical analysis was performed using Student's unpaired t-test or the
Mann–Whitney U-test for non-normally distributed variables. For dis-
crete variables, the chi-square test was used. One-way ANCOVA or the
Mann–Whitney U-test was used to assess statistical signiﬁcance for
non-normally distributed variables. P b 0.05 was regarded as statistical-
ly signiﬁcant. All parameters were analyzedwith KaplanMeier analysis.
Parameters with “crossing” curves were excluded from univariate anal-
ysis. Parameters with high clinical relevance and with low percentage
data missing (b17%) as well as with statistical signiﬁcance from univar-
iate analysis were further tested in multivariate models (Cox propor-
tional hazards analysis) which were done in two steps. At the ﬁrst
step the parameters were divided into two models, in a way to avoid
multicollinearity. Then all signiﬁcant parameters from the ﬁrst step
were further analyzed together in one multivariate model. Factors
with statistical signiﬁcance from all threemodels were further analyzed
with Kaplan–Meier analysis, both in separate and in combinations. The
hazard ratios (HR) with conﬁdence intervals (CI) and P-values were
presented. The PASW Statistics 18 (USA) statistical package was used
for all the data analyses.
The primary endpoint was all-cause mortality based on hospital re-
cords which were available for all studied patients during time period
January 2 to May 30, 2012.
3. Results
3.1. Clinical characteristics of whole study population and clinical outcome
ﬁve years after undergoing percutaneous coronary intervention (PCI)
Data were selectively presented in Table 1 and explicitly presented
in the supplementary Table. The primary endpoint was all-cause mor-
tality based on hospital records and the Death Registry at the National
Board for Welfare in Sweden. All-cause mortality after ﬁve years'
follow-up was 46.2%. Mean age was 83.7 ± 2.8 years, 62% were male,
18% were physically inactive, 10% had urinary or bowel incontinence
and 65% had a history of hypertension. Mean heart rate was 79 ±
24 beats per minute, 76% were in sinus rhythm, and 48% had ejection
fraction b 45%. Indications for PCI were STEMI (52%), NSTEMI (36%)
and unstable angina (11%). At discharge patients received treatment
with aspirin (80%), clopidogrel (89%), beta blockers (84%), ACE-I/ARBs
(59%) and statins (71%).
3.2. Clinical characteristics of those patients who died compared with
those who survived ﬁve years after undergoing percutaneous coronary
intervention (PCI)
In general, those who died were older, had a higher percentage of
ADL-dependency, higher heart rate, more often valve diseases, more
often PCI-related complications, including bleedings, cardiogenic
shock, AV-block needing temporary pacemaker, different kinds of coro-
nary artery dissections, occurredmore often in thosewho died. Howev-
er, other PCI parameters such as the number of stents, the type of stent
(baremetal or drug-eluting stents), the access site (radial artery or fem-
oral artery), one or multi-vessel disease and the indication for PCI did
Table 1
Characteristics of the study cohort between survivors and not survivors, at least 5-years after PCI.
Total Dead Alive P
N 184 84 98
Age (years) 83.7 ± 2.8 84.2 ± 3 83.2 ± 2.5 0.015
Male (%) 61.5 63.1 60.2 0.689
Social and functional status
Living alone (%), n = 182 44.5 42.9 45.5 0.526
Dependency in ADL (%), n = 182 6 10.7 2 0.014
Social support dependency (%), n = 159 27.5 32.1 23.2 0.053
Physical inactivity (%), n = 132 18.7 25.0 13.3 0.008
Clinical parameters during admission
BMI ≥ 26 kg/m2 (%), n = 166 24.9 ± 3.7 24.7 ± 4.0 25 ± 3.4 0.448
Heart rate (beats/min) (mean ± SD), n = 170 79 ± 23 84 ± 27 75 ± 20 0.012
Systolic BP (mm Hg) (mean ± SD), n = 171 150 ± 29 147 ± 34 152 ± 24 0.192
Diastolic BP (mm Hg) (mean ± SD), n = 170 84 ± 16 84 ± 16 85 ± 16 0.407
Clinical parameters at discharge
Heart rate (beats/min) (mean ± SD), n = 158 67 ± 14 71 ± 19 64 ± 9 0.004
Systolic BP (mm Hg) (mean ± SD), n = 147 138 ± 22 135 ± 20 139 ± 23 0.256
Diastolic BP (mm Hg) (mean ± SD), n = 147 72 ± 10 72 ± 10 72 ± 10 0.854
Echocardiography
EF % (mean ± SD), n = 162 48 ± 10.7 46.5 ± 11.5 49.2 ± 9.9 0.117
EF ≤ 45 (%), n = 162 42.3 42.9 41.4 0.574
MR, grade ≥ 1 (scale 0.5–4) (%), n = 152 28 35.7 21.2 0.009
AS of any grade (%), n = 143 12.1 19 3.1 0.008
TR, grade N 2 (scale 0.5–4) (%), n = 152 5.5 10.7 1.0 0.005
CVP ≥ 10 mm Hg (%), n = 126 6 9.5 3.1 0.031
ECG parameters
Atria ﬁbrillation (%), n = 175 19.8 34.5 7.1 b0.001
AV-block, different types (%), n = 174 12.6 16.7 9.2 0.160
Cardiovascular risk factors
Current smoker (%), n = 177 4.9 6 4.0 0.560
Prior smoker (%), n = 130 31.5 44.6 32.3 0.010
Hypertension (%), n = 181 64.8 71.4 58.6 0.065
Diabetes mellitus (%), n = 168 19.2 29.8 10.1 0.000
Cardiovascular diseases
Prior myocardial infarction (%), n = 180 29.1 35.7 23.2 0.078
Angina pectoris (%) n = 181 40.1 45.2 35.4 0.186
Congestive heart failure (%) n = 156 18.1 21.4 15.2 0.130
Cardiovascular interventions
Prior CABG (%), n = 181 5.5 10.7 1.0 0.004
Prior PCI (%), n = 180 6.6 7.1 6.1 0.749
Laboratory parameters at admission
Hemoglobin (g/L) (mean ± SD) n = 169 133 ± 16 131 ± 15 134 ± 16 0.136
eGFR (ml/min) (mean ± SD) n = 164 53 ± 17 50 ± 19 55 ± 15 0.038
Total cholesterol (mmol/L) (mean ± SD) 4.5 ± 1.1 4.4 ± 1.1 4.6 ± 1 0.441
Medications at admission
Aspirin (%) 46.7 56 38.8 0.021
Beta-blockers (%) 52.2 57.1 48.0 0.164
ACE-inhibitors (%) 17.6 23.8 12.2 0.032
Loop diuretics (%) 22.5 33.3 13.3 0.001
PCI indication
STEMI (%) 35.7 35.4 35.90 0.95
NSTEMI (%) 51.6 51.9 51.50 0.88
Unstable angina pectoris (%) 11 11.4 10.70 0.87
Activities of daily living, ADL. Body mass index, BMI. Mitral valve regurgitation, MR. Aortic valve stenosis, AS. Tricuspid valve regurgitation, TR. Central venous pressure, CVP. Estimated
glomerular ﬁltration rate, eGFR. ST-segment elevation myocardial infarction, STEMI. Non-ST-segment elevation myocardial infarction, NSTEMI.
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died were more likely to be prior smokers and had a higher percentage
of diabetes mellitus and prior myocardial infarction. No signiﬁcant dif-
ferences in cerebrovascular diseases such as prior stroke or transient is-
chemic attack were found between the two groups. In all patients, a
total of 24 co-morbidities were registered. Among them renal insufﬁ-
ciency with eGFR ≤ 30 ml/min was more frequently seen in those
who died. Regarding medications, during admission, those who died
had more prescriptions of aspirin, warfarin, ACE-I, loop diuretics and
sulfonylureas. At discharge, all patients, regardless of whether dead oralive, had signiﬁcantly increased use of aspirin, beta-blockers, ACE-I, di-
uretics and statins compared with those during admission. However, at
discharge thosewhodied had less aspirin, beta-blockers and statins, but
more warfarin, diuretics and proton pump inhibitors compared with
those who were alive.
3.3. Predictors of ﬁve-year all cause mortality
As shown in Table 2, univariate analyses demonstrated 32 signiﬁcant
predictors of ﬁve-year mortality. Further analyses in 2 different
Table 2
Univariate analysis of all-cause mortality, at least ﬁve years after PCI. All factors in Table 1
were subject to analysis. Only signiﬁcant prognostic predictors are listed in the table.
HR 95% CI P
Social and functional status
Physical inactivity 2.4 1.4–4.2 0.002
Walking aid dependency 2.8 1.7–4.6 b0.001
Dependency in activities of daily living 2.9 1.4–5.8 0.003
Urinary or bowel incontinence 2.4 1.2–4.7 0.007
Clinical parameters
Heart rate N 75 beats/min, at admission. 2.1 1.3–3.4 0.001
Heart rate N 65 beats/min, at discharge. 2.0 1.2–3.3 0.006
Poor R-wave progression 1.7 1.0–2.9 0.040
Dilated right atrium 1.9 1.1–3.4 0.023
Signiﬁcant aortic valve stenosis 2.2 1.2–3.9 0.005
Mitral valve regurgitation grade ≥ 1a 2.2 1.3–3.6 0.001
Tricuspid valve regurgitation grade N 2a 5.3 2.5–11.1 b0.001
Pulmonary pressure ≥ 40 mm Hg 1.8 1.0–3.2 0.024
Central venous pressure ≥ 10 mm Hg 2.6 1.2–5.5 0.013
Complications during admissionb 2.0 1.2–3.5 0.007
Laboratory parameters
Estimated glomerular ﬁltration rate ≤ 30 ml/min,
at admission.
3.5 1.8–6.9 b0.001
High white blood cell count, at admission. 1.0 1.0–1.1 0.004
Hemoglobin gm/L, at discharge. 1.8 1.0–3.3 0.038
Cardiovascular risk factors
Prior smoker 1.8 1.0–3.1 0.030
Diabetes mellitus 2.3 1.4–3.8 b0.001
Cardiovascular diseases
Prior coronary artery bypass grafting 2.9 1.4–6.0 0.002
Atrial ﬁbrillation 2.8 1.8–4.5 b0.001
Co-morbidities
Dementia 2.2 1.1–4.2 0.015
Rheumatic diseases 2.0 1.1–3.6 0.022
Medications, at admission
Aspirin 1.7 1.1–2.6 0.016
ACE-I/ARBs 1.8 1.1–3.0 0.019
Loop diuretics 2.5 1.5–3.9 b0.001
Medications, at discharge
Beta blockers 0.3 0.1–0.7 0.004
Statins 0.5 0.3–0.8 0.013
Warfarin 2.1 1.0–4.1 0.031
Proton pump inhibitors 1.7 1.0–2.8 0.027
Corticosteroids 2.3 1.2–4.6 0.012
Sulfonylureas 2.7 1.5–5.0 0.001
a Scale 0.5–4.
b Local and systemic complications.
Table 3B
Multivariate analysis of all-cause mortality, at least ﬁve years after PCI (step 1 model 2).
Predictors HR 95% CI P
Diabetes mellitus 1.6 0.9–2.9 0.078
Dependency in activities of daily living 2.5 1.1–5.6 0.029
Mitral valve regurgitation grade ≥ 1 (scale, 0.5–4) 1.9 1.1–3.3 0.013
Atrial ﬁbrillation 2.4 1.4–4.2 0.002
Prior coronary artery bypass grafting 2.0 0.8–4.9 0.095
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dictors: atrial ﬁbrillation, eGFR ≤ 30 ml/min, tricuspid valve regurgita-
tion grade N 2 (scale 0.5–4), dependency in activities of daily living
and mitral valve regurgitation grade ≥ 1 (scale 0.5–4) (Tables 3A–3B).
Above signiﬁcant predictors were ﬁnally analyzed all together in one
model resulting in atrial ﬁbrillation, eGFR ≤30 ml/min and mitral
valve regurgitation grade ≥ 1 (scale 0.5–4) as independent predictors
of all-cause mortality (Table 3C). Kaplan Meier analysis of predictors
fromboth steps ofmultivariate analysis demonstrated signiﬁcant differ-
ences in survival in whole population, not only in separate but also in
combinations (Figs. 2–4).Table 3A
Multivariate analysis of all-cause mortality, at least 5 years after PCI (step 1, model 1).
Predictors HR 95% CI P
Left ventricular ejection fraction ≤ 35% 1.8 0.8–3.8 0.102
Prior myocardial infarction 1.3 0.7–2.5 0.319
Tricuspid valve regurgitation grade N 2 (scale, 0.5–4) 3.9 1.6–9.6 0.002
Estimated glomerular ﬁltration rate ≤ 30 ml/min 4.0 1.8–10.0 0.003
Hemoglobin ≤ 110 g/l, at admission 1.2 0.5–3.8 0.6074. Discussion
The present study, to our knowledge for the ﬁrst time, identiﬁed
prognostic predictors for death ﬁve years after undergoing percutane-
ous coronary intervention (PCI) due to acute coronary syndrome in an
octogenarian patient cohort from daily clinical practice (Fig. 5).
In the present study, the death rate of all-cause mortality ﬁve years
after PCI was 46% which is not high in a population with a mean age
of 83 years. However, there were substantial differences in mortality
rate between those with more than one risk predictor (16.5% of patient
population with mortality rate, 80%) and those with less than one risk
predictor (83.5% of patient population with mortality rate, 39%). Kaplan
Meier survival analyses showed a mean Survival time at 31 months
with conﬁdence interval (22–41) and 71 monthswith conﬁdence inter-
val (64–77) in high and low risk groups, respectively.
There was no statistical signiﬁcant difference in survival rate be-
tween those with STEMI and those with NSTEMI.
Up to now limited data about prognostic prediction in patients aged
≥ 80 years with acute coronary syndrome were available. Therefore
decision-making about PCI has been highly empirical. The majority of
our patientsweremale, hadwell-controlled blood pressure, had accept-
able BMI, had normal hemoglobin level and were in sinus rhythm. Only
6.6% had chronic obstructive pulmonary disease. Such patient proﬁle in-
deed reﬂects the reality of daily clinical practice in an elderly patient
population≥ 80 years,where evidence of favorable effects of PCI is lack-
ing. Therefore decision-making has until now often been in favor of rel-
atively healthier elderly individuals. This empiric decision-making has
discriminated other elderly patients who might have had beneﬁted
from PCI. Nevertheless, despite this selection bias our study population
is still representative for this aged group. As a matter of fact, no exclu-
sion was applied when patients were included in this study except
age b 80 years and patients not belonging to our hospital's catchment
area. Despite the current clinical realityworldwide that thehealthier oc-
togenarian patients are often favored for PCI in the setting of ACS in the
absence of evidence-based recommendation, our patient cohort is actu-
ally not so healthy. A substantial proportion of them have different co-
morbidities. For instance 65% had hypertension, 24% had AF, 42% had
left ventricular ejection fraction b 45%, 27% were in need for social sup-
port and 51% and 41% were with vision and hearing disorders
respectively.
In order to establish a multivariate predictive model, 145 parameters
were registered and divided into 14 domains. To avoid multicollinearity
multivariate analysis was done in two steps to pick up all predictors with
prognostic predictive value. By Kaplan Meier analysis we were able to
further evaluate predictors. For instancemoderate tricuspid valve regur-
gitation gave signiﬁcant results in KaplanMeier analysis, but not in mul-
tivariate analysis indicating the high risk for type I statistical error.Table 3C
Multivariate analysis of all-cause mortality, at least 5 years after PCI (step 2).
Predictors HR 95% CI P
Estimated glomerular ﬁltration rate ≤ 30 ml/min 3.0 1.2–7.8 0.019
Dependency in activities of daily living 1.6 0.6–4.0 0.273
Mitral valve regurgitation grade ≥ 1 (scale, 0.5–4) 1.8 1.0–3.2 0.043
Atrial ﬁbrillation 2.8 1.5–5.1 0.001
Tricuspid valve regurgitation grade N 2 (scale, 0.5–4) 2.1 0.9–5.1 0.085
Fig. 2. Kaplan–Meier survival curve for whole study population: A: Tricuspid valve regurgitation as one of prognostic predictors. B: Mitral valve regurgitation as one of prognostic predic-
tors. C: Atrial ﬁbrillation as one of prognostic predictors. D: eGFR ≤ 30 ml/min as one of prognostic predictors. E: Dependency in activities of daily living as one of prognostic predictors.
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Fig. 3. Impact of accumulation of prognostic predictors from ﬁrst stage of multivariate
analysis on survival.
Forrest plot of CI of HR
0,1 1 10
HR
DEPENDENCY IN ADL            (P 0.273)
MODERATE TR                       (P 0.085)
MODERATE MR                      (P 0.043)
eGFR ≤30 ML/MIN                    (P 0.019)
ATRIAL FIBRILLATION            (P 0.001)
Fig. 5. Forrest plot of different prognostic factors.
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identiﬁed as independent predictors for all-cause death; atrial ﬁbrilla-
tion, estimated glomerular ﬁltration rate (eGFR)≤ 30 ml/min andmitral
valve regurgitation grade ≥ 1 (scale 0.5–4). Some of them are expected
such as eGFR ≤ 30 ml/min and atrial ﬁbrillation. Some of them are not
unexpected but have surprisingly high impact on prognosis after PCI
such as mitral valve regurgitation grade≥ 1 (scale 0.5–4). This might in-
dicate thatmitral regurgitation is a bettermarker of left ventricular func-
tion than ejection fraction which did not have any impact on survival in
our study. Atrial ﬁbrillation and eGFR ≤ 30 ml/min were the strongest
predictors for all-cause death. It is well known that AF is usually com-
bined with severe cardiovascular comorbidity [17] and eGFR ≤ 30 indi-
cates severe renal failure which has itself poor prognosis, and is also
usually combined with cardiovascular comorbidity [18]. Treatment
with beta blockers had a strong positive effect on the prognosis which
is consistent with available randomized trials in patients with ischemic
heart disease indicating that beta blockers are not only beneﬁcial in
younger patients but also in octogenarians.Fig. 4. Impact of accumulation of prognostic predictors from last stage ofmultivariate anal-
ysis on survival.Our study also implies that among patients ≥ 80 years there is in-
deed a big subgroup of patients who have only few risk factors for in-
creased death, with a relative excellent survival rate ﬁve years after
PCI. However further studies are needed to randomize octogenarian pa-
tients between PCI and without PCI and then comparatively study their
prognostic risk factors.
5. Study limitations
This is a secondary analysis of clinical data. Despite effort in catching
up information as much as possible there are still data missing. More-
over, asmentioned in the discussion, patients in this cohort were select-
edwhich however is themain stream in our daily clinical practice and is
impossible to be avoided in the view of limited evidence available.
6. Conclusion
In an octogenarian patient cohort who suffered from acute coronary
syndrome and undergone PCI in daily clinical practice, we were able to
identify prognostic predictors for all-cause death after ﬁve years of
follow-up.
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